Multitargeted docking approach reveals droxidopa against DNA replication and repair-related protein of cervical cancer [PDF]
Scientific ReportsCervical cancer begins in the cells lining the cervix and is caused by persistent infection with certain types of human papillomavirus (HPV). Initially, it has no symptoms, and later it causes pelvic pain, abnormal vaginal bleeding, and pain during ...
Ahad Amer Alsaiari +9 more
doaj +4 more sources
Belly dancer syndrome improved by withdrawal of droxidopa and amantadine [PDF]
Clinical Case Reports, 2023 Key Clinical Message A man hospitalized for cerebral infarction developed drug‐induced belly dancer syndrome, which improved after withdrawal of droxidopa and amantadine.
Mihiro Kaga +6 more
doaj +5 more sources
Use of droxidopa for blood pressure augmentation after acute spinal cord injury: case reports [PDF]
Acute and Critical Care, 2022 Hypotension secondary to autonomic dysfunction is a common complication of acute spinal cord injury (SCI) that may worsen neurologic outcomes. Midodrine, an enteral α-1 agonist, is often used to facilitate weaning intravenous (IV) vasopressors, but its ...
Christopher S. Hong +11 more
doaj +4 more sources
Psychometric validation of a patient-reported single-item assessment of ‘Good Day Bad Day’ in a neurogenic orthostatic hypotension population treated with droxidopa [PDF]
Journal of Market Access & Health Policy, 2022 Background Symptoms of neurogenic orthostatic hypotension (nOH), including lightheadedness/dizziness, presyncope, syncope, and falls, can lead to impaired functional ability and reduced quality of life.
Clément François +5 more
doaj +3 more sources
Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report [PDF]
Journal of Medical Case Reports, 2020 Background Droxidopa is an oral treatment for the stepwise treatment of neurogenic orthostatic hypotension from autonomic dysfunction. It has been shown to be useful predominantly with neurogenic orthostatic hypotension secondary to Parkinson’s disease ...
Annie H. Ho +4 more
doaj +3 more sources
L-DOPA and Droxidopa: From Force Field Development to Molecular Docking into Human β2-Adrenergic Receptor [PDF]
Life, 2022 The increasing interest in the molecular mechanism of the binding of different agonists and antagonists to β2-adrenergic receptor (β2AR) inactive and active states has led us to investigate protein–ligand interactions using molecular docking calculations.
Andrea Catte +3 more
doaj +3 more sources
Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review. [PDF]
Cureus, 2023 Neurogenic orthostatic hypotension (nOH) is a disabling problem of autonomic dysfunction in patients with Parkinson’s disease, which is associated with poor quality of life and higher mortality rates.
Hoxhaj P +12 more
europepmc +4 more sources
Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach
International Journal of General Medicine, 2021 Fahd Amjad,1 Brett Polenchar,2 Antonella Favit3 1Department of Neurology, Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC, USA; 2Business Insights, Lundbeck, Deerfield, IL, USA; 3Medical Affairs, Lundbeck, Deerfield, IL ...
Amjad F, Polenchar B, Favit A
doaj +4 more sources
Health Science Reports, 2021 Background and Aims Patients with neurogenic orthostatic hypotension (nOH) due to autonomic dysfunction may also experience supine hypertension (defined as supine systolic blood pressure [SBP] ≥140 mmHg).
Meghana S Karnik-henry +2 more
exaly +3 more sources
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
BMC Neurology, 2017 Background Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies.
Italo Biaggioni +2 more
exaly +4 more sources